Immutep Receives FDA Fast Track designation for NSCLC treatment
- Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)
- The designation — Immute p’s second for the drug — is specifically for efti when used in combination with cancer drug pembrolizumab
- It gives Immute p access to more frequent interactions with the FDA and offers the potential for expedited development and review of the treatment
- The designation is granted based on “encouraging” phase two clinical data for efti in first-line NSCLC announced by Immute p earlier this year
- Shares in the company are up 8.33 per cent and trading at 26 cents as of 12:41 pm AEDT
